Dr. Esteva Discusses Adjuvant Trastuzumab in HER2+ Breast Cancer

Francisco J. Esteva, MD, PhD
Published: Tuesday, Jun 26, 2018



Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses adjuvant trastuzumab (Herceptin) in HER2-positive early breast cancer.

Data presented at the 2018 ASCO Annual Meeting showed that a 6-month course of adjuvant trastuzumab was a noninferior schedule regarding disease-free survival (DFS) when compared with the standard 12-month regimen. Esteva says that the question now is how these data fit into the standard of care.

This data was from the phase III PERSEPHONE trial, which randomized 4088 patients across 152 sites in the United Kingdom to receive trastuzumab for 6 months (n = 2043) or 12 months (n = 2045). At 5 years, the 4-year DFS rate was 89.8% with 12 months of trastuzumab compared with 89.4% with the 6-month course, which met the criteria for noninferiority.

Esteva says that until there is more information released on this shorter schedule, the standard in the United States will remain 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer.
SELECTED
LANGUAGE


Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses adjuvant trastuzumab (Herceptin) in HER2-positive early breast cancer.

Data presented at the 2018 ASCO Annual Meeting showed that a 6-month course of adjuvant trastuzumab was a noninferior schedule regarding disease-free survival (DFS) when compared with the standard 12-month regimen. Esteva says that the question now is how these data fit into the standard of care.

This data was from the phase III PERSEPHONE trial, which randomized 4088 patients across 152 sites in the United Kingdom to receive trastuzumab for 6 months (n = 2043) or 12 months (n = 2045). At 5 years, the 4-year DFS rate was 89.8% with 12 months of trastuzumab compared with 89.4% with the 6-month course, which met the criteria for noninferiority.

Esteva says that until there is more information released on this shorter schedule, the standard in the United States will remain 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x